Neal W Jorgensen Selected Research

Cardiovascular Diseases (Cardiovascular Disease)

10/2022	Resistin and risks of incident heart failure subtypes and cardiac fibrosis: the Multi-Ethnic Study of Atherosclerosis.
1/2020	Cholesterol mass efflux capacity and risk of peripheral artery disease: The Multi-Ethnic Study of Atherosclerosis.
1/2019	Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque.
1/2017	Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis.
1/2016	Socioeconomic Status and Poor Health Outcome at 10 Years of Follow-Up in the Multi-Ethnic Study of Atherosclerosis.
6/2013	Using imputed pre-treatment cholesterol in a propensity score model to reduce confounding by indication: results from the multi-ethnic study of atherosclerosis.
4/2013	Coronary calcium score predicts cardiovascular mortality in diabetes: diabetes heart study.
8/2011	Association of lipoprotein-associated phospholipase A(2) and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA).
10/2003	Decisional attributes of patients with diabetes: the aspirin choice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Neal W Jorgensen Research Topics

Disease

14	Atherosclerosis 10/2022 - 08/2011
9	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 10/2003
4	Coronary Disease (Coronary Heart Disease) 01/2019 - 04/2010
2	Peripheral Arterial Disease 01/2020 - 01/2017
2	Inflammation (Inflammations) 01/2018 - 04/2014
2	Hypertension (High Blood Pressure) 01/2016 - 05/2013
1	Heart Failure 10/2022
1	Fibrosis (Cirrhosis) 10/2022
1	Diabetes Mellitus 01/2019
1	Stroke (Strokes) 01/2019
1	Lung Neoplasms (Lung Cancer) 11/2018
1	Atrial Fibrillation 01/2018
1	Atrial Remodeling 12/2016
1	Melanoma (Melanoma, Malignant) 01/2016
1	Neoplasms (Cancer) 01/2016
1	Skin Neoplasms (Skin Cancer) 01/2016
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2016
1	Cognitive Dysfunction 01/2016
1	Coronary Artery Disease (Coronary Atherosclerosis) 04/2014
1	Gout 05/2013
1	Hyperuricemia 05/2013
1	Type 2 Diabetes Mellitus (MODY) 04/2013

Drug/Important Bio-Agent (IBA)

6	CalciumIBA 12/2021 - 04/2010
4	CholesterolIBA 01/2020 - 05/2013
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 06/2013
3	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2018 - 08/2011
2	Biomarkers (Surrogate Marker)IBA 10/2022 - 04/2014
2	HDL LipoproteinsIBA 01/2020 - 01/2019
2	CME-Carbodiimide (CMEC)IBA 01/2020 - 01/2019
2	C-Reactive ProteinIBA 05/2015 - 04/2014
1	ResistinIBA 10/2022
1	pro-brain natriuretic peptide (1-76)IBA 10/2022
1	Lipoproteins (Lipoprotein)IBA 12/2021
1	HDL CholesterolIBA 01/2019
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 12/2016
1	Apolipoproteins E (ApoE)IBA 01/2016
1	Dihydrotachysterol (AT 10)IBA 01/2016
1	E-SelectinIBA 05/2015
1	Fibrinogen (Factor I)FDA Link 05/2015
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 05/2015
1	fibrin fragment D (D-dimer)IBA 05/2015
1	Interleukin-6 (Interleukin 6)IBA 05/2015
1	LDL CholesterolIBA 04/2014
1	Gonadal Steroid Hormones (Sex Hormones)IBA 05/2013
1	Uric Acid (Urate)IBA 05/2013
1	urate transporterIBA 05/2013
1	Adenosine Triphosphate (ATP)IBA 05/2013
1	Particulate MatterIBA 11/2012
1	Blood Glucose (Blood Sugar)IBA 01/2012
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 10/2003

Therapy/Procedure

1	Ambulatory Care (Outpatient Care) 10/2022